TL;DR
It is proposed that the upregulated lncRNA ENSG00000265613 may enhance malignancy by stabilizing the RNA target ENSG00000582008 in luminal A breast cancer, particularly given its established role in oncogenesis.
The latest functional genomics strategies used to examine NCRNAS are discussed and their transformative ability in accurate therapy is highlighted, highlighting their transformative ability in accurate therapy.
This thesis demonstrates that the integration of refined isomiR and tRF profiles within targeted liquid biopsy populations (TEPs and PD), supported by advanced bioinformatics tools like miRGalaxy, significantly enhances the accuracy and sensitivity of cancer diagnosis.
Tr-lncRNA-derived MPs represent a previously underexplored class of potentially functional molecules associated with cancer clinical annotation and may serve as biomarkers for disease progression.
This study uncovers a therapeutic vulnerable lncRNA-centric circuitry and provides compelling preclinical evidence for the development and application of a novel RNA targeting-LNP based therapy for treatment of myeloid leukemia.
These findings call for a revised molecular dogma in which the noncoding genome is recognized as a major regulator of cellular function, oncogenic transformation, and immune surveillance.
A mechanism wherein SChLAP1 modulates AR signaling to promote PCa growth and progression is suggested, suggesting its molecular mechanism and potential to be used as a therapeutic target or biomarker.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
